Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 8Sarcoma 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Lymphoma 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Rectal Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Adenocarcinoma, Follicular 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pleural Effusion, Malignant 2Neuroendocrine Tumors 2Mesothelioma 2Melanoma 2Lymphoma, B-Cell 2Liver Neoplasms 2Kidney Neoplasms 2Colonic Neoplasms 2

Interventions

belzutifan 3gallium Ga 68 dotatate 2vatalanib 1tanespimycin 1Sunitinib 1PT2385 1Oxygen-15 1Fluorodeoxyglucose F18 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × von Hippel-Lindau Disease × Fluorodeoxyglucose F18 × Clear all
NCT00088374 2012-07-27

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
9 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡